Mode of death and predictors of mortality in adult Fontan survivors: A Japanese multicenter observational study.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 Feb 2019
Historique:
received: 16 07 2018
revised: 28 08 2018
accepted: 03 09 2018
pubmed: 12 9 2018
medline: 28 8 2019
entrez: 12 9 2018
Statut: ppublish

Résumé

Mortality rates may be high in adult Fontan patients; however, the clinical determinants remain unclear. We conducted a prospective multicenter study of adult Fontan survivors to determine the 5-year mortality rate and clarify the determinants. We followed 600 adult Fontan survivors from 40 Japanese institutions (307 men, 28 ± 7 years old, follow-up: 18 ± 6 years). The New York Heart Association (NYHA) functional class I and II was 51% and 42%, respectively. During the follow-up period of 4.1 ± 1.6 years, 33 patients died, and the 5-year survival rate was 93.5%. The mode of death was heart failure in 11 patients (34%), arrhythmia or sudden death in 8 (24%), cancer in 5 (15%), perioperative problems and hemostatic problems in 4 each (12% for each), and infection in 1 (3%). Left isomerism, prior hospitalization, protein losing enteropathy (PLE), pulmonary arteriovenous fistulae, NYHA functional class, impaired hemodynamics, hyponatremia, hepatorenal dysfunction, and use of diuretics were associated with a high mortality rate (p < 0.05-0.0001). Further, PLE (hazard ratio [HR]: 14.4), left isomerism (HR: 3.5), and NYHA (HR: 2.4) independently predicted a high 5-year high mortality (p < 0.05 for all). The incidence of cancer-related mortality increased markedly with age >40 years. Majority of the Japanese adult Fontan survivors had good functional status, with an acceptable 5-year survival rate. However, the significant prevalence of non-cardiac mortality highlights Fontan pathophysiology as a multi-organ disease that requires a multidisciplinary management strategy to improve the long-term outcome.

Sections du résumé

BACKGROUND BACKGROUND
Mortality rates may be high in adult Fontan patients; however, the clinical determinants remain unclear.
PURPOSE OBJECTIVE
We conducted a prospective multicenter study of adult Fontan survivors to determine the 5-year mortality rate and clarify the determinants.
METHOD AND RESULTS RESULTS
We followed 600 adult Fontan survivors from 40 Japanese institutions (307 men, 28 ± 7 years old, follow-up: 18 ± 6 years). The New York Heart Association (NYHA) functional class I and II was 51% and 42%, respectively. During the follow-up period of 4.1 ± 1.6 years, 33 patients died, and the 5-year survival rate was 93.5%. The mode of death was heart failure in 11 patients (34%), arrhythmia or sudden death in 8 (24%), cancer in 5 (15%), perioperative problems and hemostatic problems in 4 each (12% for each), and infection in 1 (3%). Left isomerism, prior hospitalization, protein losing enteropathy (PLE), pulmonary arteriovenous fistulae, NYHA functional class, impaired hemodynamics, hyponatremia, hepatorenal dysfunction, and use of diuretics were associated with a high mortality rate (p < 0.05-0.0001). Further, PLE (hazard ratio [HR]: 14.4), left isomerism (HR: 3.5), and NYHA (HR: 2.4) independently predicted a high 5-year high mortality (p < 0.05 for all). The incidence of cancer-related mortality increased markedly with age >40 years.
CONCLUSIONS CONCLUSIONS
Majority of the Japanese adult Fontan survivors had good functional status, with an acceptable 5-year survival rate. However, the significant prevalence of non-cardiac mortality highlights Fontan pathophysiology as a multi-organ disease that requires a multidisciplinary management strategy to improve the long-term outcome.

Identifiants

pubmed: 30201381
pii: S0167-5273(18)34483-8
doi: 10.1016/j.ijcard.2018.09.002
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

74-80

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2018. Published by Elsevier B.V.

Auteurs

Hideo Ohuchi (H)

Department of Pediatric Cardiology and Adult Congenital Heart Disease, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan. Electronic address: hohuchi@ncvc.go.jp.

Kei Inai (K)

Pediatric Cardiology, Tokyo Women's Medical University, Shinjuku, Tokyo, Japan.

Makoto Nakamura (M)

Cardiology, Fukuoka Children's Hospital, Fukuoka, Fukuoka, Japan.

In-Sam Park (IS)

Pediatric Cardiology, Sakakibara Heart Institution, Fuchu, Tokyo, Japan.

Mamie Watanabe (M)

Pediatric Cardiology, Kyushu Hospital (JCHO), Kitakyushu, Fukuoka, Japan.

Ono Hiroshi (O)

Cardiology, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan.

Ki-Sung Kim (KS)

Cardiology, Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan.

Hisanori Sakazaki (H)

Pediatric Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan.

Kenji Waki (K)

Pediatric Cardiology, Kurashiki Central Hospital, Kurashiki, Okayama, Japan.

Hiroyuki Yamagishi (H)

Pediatrics, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Kenichiro Yamamura (K)

Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan.

Kenji Kuraishi (K)

Pediatric Cardiology and Neonatology, Ogaki Municipal Hospital, Ogaki, Gifu, Japan.

Masaru Miura (M)

Cardiology, Tokyo Metropolitan Children's Medical Center, Fuchu, Tokyo, Japan.

Michikazu Nakai (M)

Preventive Medicine and Epidemiologic Informatics, Center for Cerebral and Cardiovascular Center, Japan.

Kunihiro Nishimura (K)

Preventive Medicine and Epidemiologic Informatics, Center for Cerebral and Cardiovascular Center, Japan.

Koichiro Niwa (K)

Cardiology, St Luke's International Hospital, Chuo-ku, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH